Sanja Zepcan, PharmD, BCPS, BCOP

Finally, Zepcan and Ali reflect on the single most important lessons for pharmacists new to menin inhibitor therapy and share what they wish they'd known on day one.

Zepcan walks through what a complete pharmacist-to-pharmacist handoff should include when a patient with AML on a menin inhibitor moves from an academic center to community care, covering dosing history, QTc and laboratory test baselines, and documented counseling.

In this episode, Ali tackles the operational barriers that prevent patients from starting menin inhibitors despite being approved.

Zepcan establishes the monitoring timeline pharmacists need to implement, including QTc surveillance intervals, laboratory testing schedules, and symptom escalation protocols.

In this episode, Ali outlines the non-negotiable items on the first-fill consultation checklist, including baseline ECG requirements, medication review for drug interactions, and enrollment in manufacturer support programs.

Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.

Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.

Choosing revimumab vs ziftomab in NPM1 AML depends on KMT2A status, transplant plans, drug interactions, adherence, and QTc monitoring.

Menin inhibitors show promising AML responses—revumenib enables remissions and transplant bridging, while new combinations target KMT2A and NPM1.

Menin inhibitors offer new hope in relapsed KMT2A/MP1 AML, controlling disease to reach remission and allogeneic stem cell transplant.

Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.